Hansa Biopharma Ab · OMXSTO:HNSA
Hansa Biopharma Ab — Q1 2024 Earnings Presentation
15 slides from Hansa Biopharma Ab's earnings presentation, Apr 18, 2024
Slide 1: Conference Call Presentation Q1 2024
Conference Call Presentation Q1 2024 Lund, April 18, 2024
Slide 2: Forward-looking statements
Forward-looking statements This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occ
Slide 3: Strong commercial performance in the first quarter; Raised SEK ~372m in directed share issue
Strong commercial performance in the first quarter; Raised SEK ~372m (USD ~34.6m) in a directed share issue Q1: Second consecutive quarter Pipeline: Clinical programs continue 1 with solid IDEFIRIX product sales 2 to progress as planned ü SEK 47m in IDEFIRIX product sales ü Anti-GBM disease: • Growt
Slide 4: Continued progress against our key launch metrics led by in-market growth
Continued progress against our key launch metrics led by in-market growth Market Market Patient Transplant Center Building Access Identification Readiness & Use 7 14 36 ~50 - Medical guidelines 10 Market access secured in 8 25 implemented on a national 14 European markets or 75% Post Approval Study
Slide 5: Strong momentum in ConfIdeS trial: More than 20% increase in activated sites during Q1
Strong momentum in ConfIdeS trial: More than 20% increase in activated sites during Q1 will accelerate randomization ConfIdeS phase 3 trial will further advance potential for imlifidase to address unmet need in desensitization Involved ConfIdeS sites cover more than 20% of U.S. ConfIdeS total transp
Slide 6: Significant progress in anti-GBM trial underpins potential for imlifidase in autoimmune disease
Significant progress in anti-GBM trial underpins potential for imlifidase in autoimmune disease First in class IgG Anti-GBM as catalyst Opportunity to expand cleaving enzyme to enter autoimmune into several IgG mediated autoimmune conditions Potential indication universe (not exhaustive) Unique anti
Slide 7: Strong momentum across the pipeline in areas of high unmet need
Strong momentum across the pipeline in areas of high unmet need Phase 1 Phase 2 Phase 3 HNSA-5487 (Lead from NiceR) Antibody Mediated Rejection (AMR) US ConfIdeS Study in kidney • Encouraging first read-out • Primary endpoint met • 122 patients enrolled; Completed • Ongoing collection of Completed •
Slide 8: Strong commercial performance with total Q1 revenue and product sales
Strong commercial performance with total Q1 revenue of SEK 56m including product sales of SEK 47m Product sales improved +9% vs Q4 2023 and +231% vs Q1 2023; Growth driven by uptake in U.K., France and Germany Revenue (Q/Q) Product Sales (Q/Q) Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q1'23 Q2'23 Q3'23 Q4'23 Q1
Slide 9: Continued investments in commercialization and R&D activities
Continued investments in commercialization and R&D activities SG&A expenses (Q/Q) R&D expenses (Q/Q) Operating loss (Q/Q) Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 -182 -176 -159 -103 -91 -93 -96 -103 -202 -112 -106 -115 -108 -228 SEKm SEKm SEKm -129 S
Slide 10: Extended our cash runway into 2026 through a USD 34.6m directed share issue
Extended our cash runway into 2026 through a USD 34.6m directed share issue Cash position post recent Operating cash flow (Q/Q) Cash & short-term investments (Q/Q) directed share issue Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 1,287 SEK Extending our cash runway into 2026 1,103 ~372m -173 (USD 34.6m) -183 908 -
Slide 11: Q4 2023 achievements and upcoming milestones 2024/25
Q4 2023 achievements and upcoming milestones 2024/25 2023 2024 2025 Q4 2023 HNSA-5487 (Lead NiceR candidate): GBS Phase 2: - U.S. ConfIdeS (Kidney tx) Phase 3: ✓ - Outcome of comparative efficacy analysis High-level data readout from Phase 1 BLA submission Long-term follow-up (Kidney tx): Genethon C
Slide 12: Q&A
Q&A Visit our website hansabiopharma.com … at Hansa Biopharma, we envision a world where all patients with rare immunologic diseases can lead long and healthy lives… 12
Slide 13: Broad clinical pipeline in transplantation, autoimmune diseases, and gene therapy
Broad clinical pipeline in transplantation, autoimmune diseases, and gene therapy Research/ Marketing Project Indication Preclinical Phase 1 Phase 2 Phase 3 Authorization Marketed Partner Next Anticipated Milestone EU: Additional agreements around EU: Kidney transplantation in highly sensitized reim
Slide 14: Contact our Investor Relations and Corporate Affairs team
Contact our Investor Relations and Corporate Affairs team Contact Calendar and events Apr 18, 2024 Interim Report for January-March 2024 Klaus Sindahl Apr 22, 2024 ABG Road Show, Stockholm VP, Head of Investor Relations May 14, 2024 Capital One Biotech Disruptors Event, New York City Mobile: +46 (0)
Slide 15: HANSAT
MZ HANSAT BIOPHARMA